← 返回

基线 [18F]FDG PET 特征与接受 CAR-T 细胞治疗的大 B 细胞淋巴瘤患者的生存和毒性相关

英文原题:Baseline [(18)F]FDG PET features are associated with survival and toxicity in patients treated with CAR T cells for large B cell lymphoma.

查看英文原题

Baseline [(18)F]FDG PET features are associated with survival and toxicity in patients treated with CAR T cells for large B cell lymphoma.

PubMed 2023/09/18(内容时间) Eur J Nucl Med Mol Imaging Q1 · IF 7.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

TMTV 和 sDmax 分别对 PFS 和 OS 具有独立预后价值。

中文摘要

CAR-T 细胞已成为复发/难治性大B细胞淋巴瘤(LBCL)的有效治疗方法。近期研究显示,sDmax(由患者体表面积标准化的两处最远病灶间距离)可能是LBCL的预后因素。本研究旨在确定与预后相关并可预测CAR-T 治疗不良事件的18F-FDG PET生物标志物。

回顾性纳入两所大学医院接受LBCL CAR-T 治疗且在输注前接受18F-FDG PET检查的患者。采用半自动方法按最大摄取值的41%勾画病灶。除临床和生物学特征外,还收集sDmax、总代谢肿瘤体积(TMTV)、最大标准摄取值(SUVmax)以及正常淋巴器官和肝脏的摄取强度。采用Kaplan-Meier法估计无进展生存期(PFS)和总生存期(OS),并记录细胞因子释放综合征(CRS)及免疫效应细胞相关神经毒性综合征(ICANS)等不良事件。

共纳入56例患者,中位随访9.7个月。多变量分析显示,TMTV(截断值36 mL)是PFS的独立预后因素(p<0.001),sDmax(截断值0.15 m⁻¹)是OS的独立预后因素(p=0.008)。不良事件方面,CAR-T 治疗前C反应蛋白>35 mg/L(p=0.006)及肝脏SUVmean>2.5(p=0.027)与2至4级CRS相关,脾脏SUVmean>1.9与2至4级ICANS相关。

TMTV和sDmax分别对PFS和OS具有独立预后价值;肝脏和脾脏平均摄取值分别与2至4级CRS和ICANS相关。将这些生物标志物纳入临床流程或有助于及早调整患者管理。

展开英文摘要原文

Chimeric antigen receptor (CAR) T cells have established themselves as an effective treatment for refractory or relapsed large B cell lymphoma (LBCL). Recently, the sDmax, which corresponds to the distance separating the two farthest lesions standardized by the patient's body surface area, has appeared as a prognostic factor in LBCL. This study aimed to identify [ 18 F]FDG-PET biomarkers associated with prognosis and predictive of adverse events in patients treated with CAR T cells.

Patients were retrospectively included from two different university hospitals. They were being treated with CAR T cells for LBCL and underwent [ 18 F]FDG-PET just before CAR T cell infusion. Lesions were segmented semi-automatically with a threshold of 41% of the maximal uptake. In addition to clinico-biological features, sDmax, total metabolic tumor volume (TMTV), SUVmax, and uptake intensity of healthy lymphoid organs and liver were collected. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. The occurrence of adverse events, such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), was reported.

Fifty-six patients were included. The median follow-up was 9.7 months. Multivariate analysis showed that TMTV (cut-off of 36 mL) was an independent prognostic factor for PFS (p < 0.001) and that sDmax (cut-off of 0.15 m -1 ) was an independent prognostic factor for OS (p = 0.008). Concerning the occurrence of adverse events, a C-reactive protein level > 35 mg/L (p = 0.006) and a liver SUVmean > 2.5 (p = 0.027) before CAR T cells were associated with grade 2 to 4 CRS and a spleen SUVmean > 1.9 with grade 2 to 4 ICANS.

TMTV and sDmax had independent prognostic values, respectively, on PFS and OS. Regarding adverse events, the mean liver and spleen uptakes were associated with the occurrence of grade 2 to 4 CRS and ICANS, respectively. Integrating these biomarkers into the clinical workflow could be useful for early adaptation of patients management.

论文信息

作者
Marchal E、Palard-Novello X、Lhomme F、Meyer ME、Manson G、Devillers A、Marolleau JP、Houot R
单位
Department of Nuclear Medicine, Amiens-Picardie University Hospital, Amiens, France. marchal.etienne@chu-amiens.fr.France
期刊
European journal of nuclear medicine and molecular imaging2024 Jan
原文标识
PubMed 37721580 · DOI 10.1007/s00259-023-06427-6